TORONTO, July 24, 2023 /PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced today a multi-target license and option agreement with ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), to advance novel, first-in-class ADCs. The collaboration will combine ImmunoGen's proprietary linker and payload technologies with ImmunoBiochem's antibodies directed against specific targets.
Read more at prnewswire.comImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
